Monoclonal Gammopathy of Undetermined Significance (MGUS)

A clinically significant condition that requires monitoring

Early detection of disease progression and emergence of comorbidities can significantly improve patient outcomes and quality of life

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clinically significant precursor to Multiple Myeloma and other haematological malignancies. Despite its non-cancerous nature, MGUS is associated with a range of comorbidities and an elevated risk of progression to malignancy, necessitating vigilant monitoring. Comprehensive diagnostics as part of regular follow-up and symptom awareness are crucial. As our understanding of MGUS and its broader implications continues to evolve, it remains imperative to remain vigilant. We need to be mindful of symptoms that develop during monitoring, to enable timely intervention to mitigate risks and enhance survival rates.

What is MGUS?

Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition of Multiple Myeloma (MM) that is characterised by the presence of a monoclonal protein (M-protein) in the blood. MGUS develops from the clonal expansion of plasma cells in the bone marrow and affects approximately 5% of the population over 50 years of age[1]. Since its discovery, understanding of MGUS pathology has increased greatly and the umbrella term MGUS now includes a number of clinically relevant conditions collectively called monoclonal gammopathy of clinical significance (MGCS).

The clinical significance of MGUS

The most clinically significant characteristic of MGUS is its potential to progress through smoldering Multiple Myeloma to Multiple Myeloma, the second most common hematological cancer which accounts for 2% of cancer diagnoses each year[2]. The risk of MGUS progression to MM is approximately 1% a year and this risk persists indefinitely (>30 years)[3]. Although, patients with MGUS can be risk stratified into those with high, medium and low risk of progression, risk is not static and can evolve over time[4]. Therefore, it is important to monitor all MGUS patients as all MGUS patients can potentially progress to MM regardless of baseline MGUS risk stratification. Importantly, outcome is worse in low-risk patients who progress compared to patients initially categorized as high-risk[5], possibly due to less frequent monitoring, leading to progression going undetected.

Why you should monitor patients with MGUS

The goal of MGUS monitoring is to detect early progression to MM and the emergence of MGUS related comorbidities. This enables timely intervention to minimize further complications and improve patient survival outcomes and quality of life. Indeed, research has shown that monitoring of patients with MGUS does lead to earlier detection and diagnosis of Myeloma, resulting in patients presenting with less end-organ damage and less morbidity at time of diagnosis[6].

Contact us to discuss support tools for monitoring MGUS patients
tbs.info.uk@bindingsite.com or visiting **thermofisher.com/bindingsite**

Binding Site
part of Thermo Fisher Scientific

What are MGUS and related monoclonal gammopathies?

Monoclonal gammopathies are a diverse group of disorders which encompasses both non-cancerous conditions such as MGUS and smouldering Multiple Myeloma, and malignant conditions e.g., Multiple Myeloma and plasma cell leukaemia. These disorders are characterised by the abnormal production of M-proteins by a population of clonally expanded plasma cells. Under normal circumstances, a diverse range of antibodies are produced by an equally diverse number of plasma cell clones. However, in monoclonal gammopathies, a single clone of plasma cells starts expanding and produces an excessive amount of a specific type of antibody, leading to the presence of monoclonal proteins in the blood.



It is essential to differentiate between these different types of monoclonal gammopathies, as their management and prognosis can vary significantly. Proper testing, including serum free light chain (sFLC) and serum protein electrophoresis (SPE) assays, is essential to identify and distinguish between these conditions.

MGUS as a condition is defined by an abnormal serum M-protein (<30 g/L) found in the absence of end-organ damage using during standard laboratory tests. This protein is produced by a clone of plasma cells that make up less than 10% of plasma cells in the bone marrow[7].

Importantly however, these clonal plasma cells do not proliferate aggressively, (i.e. are non-malignant) which is why the condition has been historically described as of "undetermined significance".

MGUS is of clinical significance

Although MGUS is non-cancerous, it is clinically important. Patients diagnosed with MGUS have a 50% higher risk of mortality (all cause death hazard ratio (HR) = 1.5) compared to the general population. Leading causes of excess mortality in MGUS are presented in the figure below.[8]



Being a precancerous condition, MGUS patients are at much greater risk of developing Multiple Myeloma or related haematolgical cancers. Approximately 1% of MGUS cases per year progress to malignant conditions such as Multiple Myeloma, Waldenström's macroglobulinemia, or other lymphoproliferative disorders[9].

Alongside an increased risk of progression to a frank malignancy, some patients with MGUS may present or develop clinical manifestations or comorbidities. In patients who meet diagnostic criteria for MGUS, comorbidities associated with M-protein or clonal plasma cells are collectively included in the term Monoclonal Gammopathies of Clinical Significance (MGCS). MGCS differs from MGUS because the M-protein produced causes complications via a number of potential mechanisms: deposition of M-protein in various organs, the M-protein may act as an autoantibody against the patient's own proteins, clonal plasma cell expansion impacting the bone marrow and normal hemopoiesis or via other, as yet unknown mechanisms[10].



MGUS patients who are monitored have better outcomes and fewer complications

Multiple Myeloma is one of the most difficult cancers to diagnose due to the nonspecific nature of symptoms that are common to many other diseases. These may include bone pain, fatigue and repeated infections[17]. Delays in the diagnosis of Multiple Myeloma can have devasting impacts on patients:

- Expanding plasma cells clones in the bone marrow can lead to bone fractures that significantly impact patients' quality of life, most significantly, vertebral fractures that can lead to paralysis.
- M-protein deposited in organs can lead to severe organ damage including loss of kidney function.

Research has shown that monitoring patients with MGUS can lead to lower rates of complications and increased overall survival compared to patients without MGUS follow-up if these patients progress to MM[6].



In summary, as well as being a precursor to Multiple Myeloma, MGUS is associated with a range of clinically significant conditions including bone disease and kidney dysfunction amongst other disorders. Regular monitoring of MGUS can improve patient outcomes by enabling early detection and intervention if MGUS develops into MGCS or progresses to Myeloma.

Contact us to discuss support tools for monitoring MGUS patients
tbs.info.uk@bindingsite.com or visiting **thermofisher.com/bindingsite**

1 Love TJ, Rögnvaldsson S, Thorsteinsdottir S, Aspelund T, Reed ER, Vidarsson B, Onundarson PT, et al. Prevalence of MGUS Is High in the iStopMM Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do. Blood / Presented at ASH 2022;140 Supplement 1:103a as doi: 10.1182/blood-2022-163169.
2 Mikhael J, Bhutani M, Cole CE. Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. Am J Med 2023 Jan;136 1:33-41. Epub 20220920 as doi: 10.1016/j.amjmed.2022.08.030.
3 Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF, Melton LJ, III. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003 2003;102 10:3759-64 as doi: 10.1182/blood-2003-03-0801 2003-03-0801 [pii].
4 Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, et al. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol 2019 Jul 18;5 9:1293-301. Epub 2019/07/19 as doi: 10.1001/jamaoncol.2019.1568.
5 Tahiru W, Izarra Santamaria A, Hultdin J, Wu WY, Späth F. Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients [eng]. Exp Hematol Oncol 2022 Feb 23;11 1:8. Epub 20220223 as doi: 10.1186/s40164-022-00259-0.
6 Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-medicare population analysis. Clin Lymphoma Myeloma Leuk 2015 2015;15 3:177-86 as doi: S2152-2650(14)00414-5 [pii];10.1016/j.clml.2014.09.004 [doi].
7 Rajkumar SV, Dimopolous MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014 2014;15 12:e538-e48. Epub 20141026 as doi: 10.1016/S1470-2045(14)70442-5.
8 Kristinsson SY, Bjorkholm M, Andersson TML, Eloranta S, Dickman PW, Goldin LR, Blimark C, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009 2009;94 12:1714-20 as doi: 10.3324/haematol.2009.010066.
9 Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ, III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002 2002;346 8:564-9 as doi: 10.1056/NEJMoa01133202 346/8/564 [pii].
10 Oganesyan A, Gregory A, Malard F, Ghahramanyan N, Mohty M, Kazandjian D, Mekinian A, Hakobyan Y. Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment [English] [Review]. Frontiers in Immunology 2022 2022-November-23;13 as doi: 10.3389/fimmu.2022.1045002.
11 Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, et al. Monoclonal gammopathy of renal significance (MGRS): when MGUS is no longer undetermined or insignificant. Blood 2012 10/9/2012;120 22:4292-5 as doi: blood-2012-07-445304 [pii];10.1182/blood-2012-07-445304 [doi].
12 Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C, editors. Handbook of Clinical Neurology. Elsevier; 2013. p. 443-59.
13 Claveau J-S, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer Journal 2022 2022/04/11;12 4:58 as doi: 10.1038/s41408-022-00661-1.
14 Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Blimark C, Mellqvist UH, Wahlin A, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 2010 2010;116 15:2651-5 as doi: blood-2010-04-282848 [pii] 10.1182/blood-2010-04-282848.
15 Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, Landgren O. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008 2008;112 9:3582-6 as doi: blood-2008-04-151076 [pii] 10.1182/blood-2008-04-151076.
16 Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica 2012 6/2012;97 6:854-8 as doi: haematol.2011.054015 [pii];10.3324/haematol.2011.054015 [doi].
17 Koshiaris C. Methods for reducing delays in the diagnosis of multiple myeloma [eng]. Int J Hematol Oncol 2019 Feb;8 1:ijh13. Epub 20190226 as doi: 10.2217/ijh-2018-0014.

Binding Site
part of Thermo Fisher Scientific